摘要
原发性十二指肠腺癌发病率低,起病很隐匿,临床症状不具典型性,预后不佳,临床上采用内镜加活检、CT等检查方法可提高诊断准确率。早诊断、早治疗对疾病的预后尤其重要,晚期患者多采用全身化疗,XELOX、FOLFOX及FOLFIRI等方案可作为晚期患者的治疗选择。近年来,随着内窥镜技术及影像学技术的进步,原发性十二指肠腺癌检出率逐渐提高,本文就原发性十二指肠腺癌的诊治现状作简要总结。
The incidence of primary duodenal adenocarcinoma is low.The onset is concealed.The clinical symptoms are not typical,and the prognosis is poor.Clinically,the use of endoscopic biopsy,CT and other methods can improve the diagnostic accuracy.Early diagnosis and early treatment are especially important for the prognosis of the disease.Systemic chemotherapy is often used in patients with advanced disease.XELOX,FOLFOX and FOLFIRI can be used as treatment options for advanced patients.In recent years,with the advancement of endoscopic techniques and imaging techniques,the detection rate of primary duodenal adenocarcinoma has gradually increased.This article briefly summarizes the diagnosis and treatment of primary duodenal adenocarcinoma.
引文
[1] Czaykowski P,Hui D.Chemotherapy in small bowel adenocarcinoma:10-year experience of the British Columbia Cancer Agency[J].Clin Oncol (R Coll Radio),2007(19):142-149.
[2] Aparicio T,Zaanan A,Svrcek M,et al.Small bowel adenocarcinoma:Epidemiology,risk factors,diagnosis and treatment[J].Digestive and Liver Disease,2014,46(2):97-104.
[3] Overman MJ,Varadhachary GR,Kopetz S,et al.Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of vater[J].J Clin Oncol,2009,27(16):2598-2603.
[4] Xiang XJ,Liu YW,Zhang L,et al.A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma [J].Anti-Cancer Drugs,2012,23(5):561-566.
[5] Gibson MK,Holcroft CA,Kvols LK,et al.Phase II study of 5-fluorouracil,doxorubicin,and mitomycin C for metastatic small bowel adenocarcinoma [J].Oncologist,2005,10(2):132-137.
[6] LI DL,LI J.Progress in the diagnosis and treatment of primary duodenal cancer [J].Journal of Liaoning Medical University,2010,31(5):473-475.[李道磊,李静.原发性十二指肠癌的诊治进展[J].辽宁医学院学报,2010,31(5):473-475.]
[7] Buchbjerg T,Fristrup C,Mortensen MB.The incidence and prognosis of true duodenal carcinomas [J].Surgical Oncology,2015,24(2):110-116.
[8] MENG FY,ZHANG FH,LIU XD,et al.Diagnosis and treatment of primary duodenal adenocarcinoma [J].Guide of China Medicine,2012,10(36):307-308.[孟凡勇,张福华,刘晓东,等.原发性十二指肠腺癌的诊断和治疗[J].中国医药指南,2012,10(36):307-308.]
[9] Suradkar K,Lebwohl B,Green P,et al.Incidence and survival for small bowel tumors over the last two decades (1991-2012):A SEER-based analysis [J].J Am Coll Surg,2016,223(4):106.
[10] CAO L,JIANG XM,XU LM,et al.Diagnosis and treatment of primary duodenal cancer [J].Clinical Medicine,2014,11(semimonthly):31-32.[曹亮,蒋小猛,许腊梅,等.原发性十二指肠癌的诊断和治疗[J].临床医学,2014,11(下):31-32.]
[11] LUO YF.Progress in the treatment and prognosis of primary duodenal adenocarcinoma [J].Modern Journal of Integrated Traditional Chinese and Western Medicine,2015,24(6):681-684.[罗云飞.原发性十二指肠腺癌治疗及预后研究进展[J].现代中西医结合杂志,2015,24(6):681-684.]
[12] Kim MJ,Choi SB,Han HJ,et al.Clinicopathological analysis and survival outcome of duodenal adenocarcinoma [J].The Kaohsiung Journal of Medical Sciences,2014,30(5):254-259.
[13] Jiang S,Zhao R,Li Y,et al.Prognosis and nomogram for predicting postoperative survival of duodenal adenocarcinoma:A retrospective study in China and the SEER database [J].Scientific Reports,2018,8(1):7940.
[14] SHI YX,CHEN WC.Diagnosis and treatment of primary duodenal adenocarcinoma[J].Chin J Gastroenterol,2018,23(6):370-373.[史玉雪,陈卫昌.原发性十二指肠腺癌诊治进展[J].胃肠病学,2018,23(6):370-373.]
[15] JING GP,CHEN TM,WU F.Two cases report and diagnostic analysis of duodenal adenoma [J].China Medical Engineering,2014,22(6):193.[井贵平,陈洮明,吴芳.十二指肠腺瘤2例报道及诊断分析[J].中国医学工程,2014,22(6):193.]
[16] ZHAO JD,YANG WQ.Diagnosis and treatment of primary duodenal adenocarcinoma [J].Anhui Medical and Pharmaceutical Journal,2013,2(17):317-319.[赵金都,杨文奇.原发性十二指肠腺癌的诊治现状[J].安徽医药,2013,2(17):317-319.]
[17] LUO Z,PU J.Comparison of clinical features and serum CA199 and CEA levels between primary duodenal malignant tumour and primary gastric cancer [J].Clinical Journal of Medical Officers,2013,41(09):904-905.[罗哲,浦江.原发性十二指肠恶性肿瘤与原发性胃癌的临床特点及血清CA199、CEA水平比较研究[J].临床军医杂志,2013,41(09):904-905.]
[18] YU LJ,LI SD,FU CG,et al.The clinical characteristics of 625 patients with malignant small bowel tumors[J].Tumor,2012,32(10):811-818.[俞利结,李淑德,傅传刚,等.小肠恶性肿瘤625例临床特征分析[J].肿瘤,2012,32(10):811-818.]
[19] CHEN B,DAI ZK,WANG CH,et al.Analysis of diagnosis,treatment and prognosis of primary malignant duodenal tumors [J].Chinese Journal of General Surgery,2017,26(10):1310-1315.[陈斌,戴正宽,王春华,等.原发性十二指肠恶性肿瘤的诊治及预后因素分析[J].中国普通外科杂志,2017,26(10):1310-1315.]
[20] CHEN N,ZHANG TL.Clinical features,diagnosis and treatment of duodenal malignant tumors [J].Journal of Peking University,2012,6(44):944-945.[陈宁,张同琳.十二指肠恶性肿瘤的临床特点及诊治[J].北京大学学报,2012,6(44):944-945.]
[21] Debang L,Xiaoying S,Tao W,et al.Outcomes of surgical resection for primary duodenal adenocarcinoma:A systematic review[J/OL].Asian Journal of Surgery(2018).https://doi.org/10.1016/j.asjsur.2018.04.005.
[22] Cloyd JM,Norton JA,Visser BC,et al.Does the extent of resection impact survival for duodenal adenocarcinoma?analysis of 1 611 cases [J].Ann Surg Oncology,2015,22(2):573-580.
[23] Onkendi EO,Boostrom SY,Sarr MG,et al.Neoadjuvant treatment of duodenal adenocarcinoma:A rescue strategy [J].J Gastrointest Surg,2012,16(2):320-324.
[24] Ecker BL,Mcmillan MT,Datta J,et al.Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma:A propensity score-matched analysis [J].Cancer,2016,122(5):693-701.
[25] Manfredi S,Thiebot T,Henno S,et al.Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen[J].J Gastrointest Surg,2009,13(12):2309-2313.
[26] Catania C,Pelosi G,Fazio N,et al.A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma[J].Acta Oncol,2010,49(1):120-121.
[27] YANG J,CHEN Y,ZHANG HM,et al.Comparison of chemotherapy and efficacy of duodenal cancer [J].Contemporary Medicine,2016,22(3):138-139.[杨锦,陈衍,张红梅,等.十二指肠癌化疗的方案和疗效比较[J].当代医学,2016,22(3):138-139.]
[28] LIU JB,CUI CX,WANG JW,et al.Chemotherapy and comparison of agents for advanced duodenal carcinoma [J].Chin J Clin Oncol,2014,41(5):320-322.[刘俊宝,崔成旭,王金万,等.晚期十二指肠癌化疗的方案和疗效比较[J].中国肿瘤临床,2014,41(5):320-322.]
[29] PAN J,QIN SK,YANG NR,et al.Clinical observation of FOLFIRI as second-line chemotherapy for advanced duodenal cancer [J].Chinese Clinical Oncology,2017,22(5):448-449.[潘军,秦叔逵,杨宁蓉,等.FOLFIRI方案二线治疗晚期十二指肠癌的临床观察[J].临床肿瘤学杂志,2017,22(5):448-449.]
[30] HUANG HX,LUO ZJ.Progress in research on primary duodenal cancer [J].Pratical Clinical Medicine,2010,11(11):136-138.[黄恒星,罗忠金.原发性十二指肠癌的研究进展[J].实用临床医学,2010,11(11):136-138.]
[31] Yu Jin Lim,Kyubo Kim.Effect of postoperative radiotherapy on survival in duodenal adenocarcinoma:A propensity score-adjusted analysis of surveillance,epidemiology,and end results database [J].Int J Clin Oncol,2018,23(3):473-481.
[32] WEI YN.Progress in the diagnosis and treatment of duodenal adenocarcinoma [J].Journal of Yangtze University (Natural Science Edition),2018,15(12):16-19.[韦杨年.十二指肠腺癌诊治进展[J].长江大学学报(自科版),2018,15(12):16-19.]
[33] ZHU YM,SHI XY,JIANG ZC,et al.Early primary duodenal adenocarcinoma:A case report and literature review [J].Journal of Practical Oncology,2014,29(4):357-360.[朱一苗,施小宇,姜招嫦,等.早期原发性十二指肠腺癌1例报道并文献回顾[J].实用肿瘤杂志,2014,29(4):357-360.]
[34] Zhanhong Chen,Miaozhen Qiu,Xiangyuan Wu,et al.Elevated baseline serum lactate dehydrogenase indicates a poor prognosis in primary duodenum adenocarcinoma patients [J].Journal of Cancer,2018,9(3):512-520.
